With earnings tumbling over the patent cliff, can diabetes and oncology transform Eli Lilly into a Big Pharma turnaround story?
Celgene shares are up more than 1,200% over the past decade. But these three headwinds could be the brick wall that sends its stock lower.
Achillion stock is among the top gainers as its experimental hepatitis C combination therapy delivers "perfect" results.
A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.
A new class of cholesterol drugs including Amgen's (AMGN) evolocumab could soon be competing for Aegerion's (AEGR) market share in HoFH patients.
Wall Street has been buying AbbVie, Allergan, and Pfizer and short-sellers have stayed away from these stocks. Here's why.
Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.
An early FDA approval, an inhaled therapy being turned away by regulators for a third time, and three positive clinical updates are this week's top biotech stories.
MannKind receives favorable news from the FDA while Vertex stuns investors. Plus, three additional biotech companies deliver encouraging clinical results.
AbbVie and Shire. Valeant and Allergan. The drugmaker deal dances are underway -- but it takes two to tango.